Hypertension
Conditions
Keywords
Hypertension, blood pressure, Aldosterone, Eplerenone, Amlodipine, Primary aldosteronism, Exercise pressor reflex, handgrip exercise, passive arm cycling, active arm cycling
Brief summary
Hypertensive patients often show an exaggerated rise in blood pressure during exercise through overactivity of the exercise pressor reflex. An increasing body of evidence suggests a role for aldosterone in augmenting the exercise pressor reflex in hypertensive humans. We hypothesize that this effect of aldosterone is mediated by its direct action on the central nervous system and that administration of mineralocorticoid receptor antagonists constitute an effective treatment for EPR overactivity in hypertension, independent of reductions in resting BP.
Detailed description
Hypertensive patients are known to display exaggerated rise in blood pressure (BP) during exercise but the underlying mechanisms are poorly understood. Traditionally, muscle afferents were dichotomized as metaboreceptors, which are activated slowly and only during intense or ischemic muscle contraction, or mechanoreceptors, which respond quickly to even mild deformation of their receptive fields. The increase in sympathetic nerve activity and BP caused by activation of these receptors, known as exercise pressor reflex, is normally buffered by activation arterial baroreceptors, which are reset to operate at higher BP range but at the same level of sensitivity. Mechanisms responsible for overactive exercise pressor reflex in hypertension remain unknown, but an increasing body of evidence suggested a role for aldosterone in regulating resting central sympathetic outflow in both hypertensive rats and humans. Experiments will be performed on 3 groups of subjects 1) stage I (140-159/90-99 mmHg) subjects with essential hypertension, 2) stage I hypertensive subjects with Primary Aldosteronism (PA), and 3) normotensive controls. All participants will attend a baseline study visit, which will include a physical examination, a medical history review, vital sign measurements, and blood and urine collection. Small electrodes will be used to measure muscle nerve activity while the subjects perform a series of exercises that include passive arm cycling, active arm cycling, rhythmic hand grip, sustained hand grip and cold pressor test. Muscle blood flow will be measured before and after hand grip exercises. A subgroup of subjects with essential hypertension and PA will be assigned to receive Eplerenone or Amlodipine on a randomized, double-blinded design. Participants will attend two weeks visits over a period of 16 weeks. Study visits include measurement of vital signs and blood samples collection. After completing 8 weeks on each medication, muscle nerve activity will be measured while performing the same exercises described in the baseline study visit.
Interventions
DRUGEplerenone
The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
DRUGAmlodipine
The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
PROCEDUREMicroneurography
Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
PROCEDURERhythmic handgrip exercise
Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
PROCEDURESustained hand grip
Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
PROCEDUREForearm blood flow
Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
PROCEDUREArm cycling exercise
Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
PROCEDURECold Pressor test
Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
Sponsors
University of Texas Southwestern Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Experiments will be performed on 3 groups of nondiabetic human subjects: * 1\) stage I (140-159/90-99 mmHg) subjects with essential hypertension. * 2\) stage I hypertensive subjects with primary aldosteronism * 3\) normotensive controls.
Exclusion criteria
* 1\) Any evidence of cardiopulmonary disease, left ventricular hypertrophy or systolic dysfunction by echocardiography. * 2\) Blood pressure averaging ≥160/100 mmHg * 3\) Estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73m2 * 4\) Diabetes mellitus or other systemic illness * 5\) Pregnancy * 6\) Hypersensitivity to nitroprusside, phenylephrine, amlodipine or eplerenone * 7\) Any history of substance abuse or current cigarette use * 8\) Any history of psychiatric illness * 9\) History of malignancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle Sympathetic Nerve Activity at Rest | 8 weeks post treatment initiation | measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Muscle Sympathetic Nerve Activity During Exercise | 8 weeks post treatment initiation | measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) during arm cycling exercise |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Amlodipine Then Eplerenone The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. | 6 |
| Eplerenone Then Amlodipine The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. | 8 |
| Total | 14 |
Baseline characteristics
| Characteristic | Amlodipine Then Eplerenone | Total | Eplerenone Then Amlodipine |
|---|---|---|---|
| Age, Continuous | 53 years STANDARD_DEVIATION 9 | 51 years STANDARD_DEVIATION 9 | 50 years STANDARD_DEVIATION 8 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 5 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 9 Participants | 4 Participants |
| Region of Enrollment United States | 6 participants | 14 participants | 8 participants |
| Sex: Female, Male Female | 0 Participants | 3 Participants | 3 Participants |
| Sex: Female, Male Male | 6 Participants | 11 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 14 | 0 / 14 |
| other Total, other adverse events | 0 / 14 | 0 / 14 |
| serious Total, serious adverse events | 0 / 14 | 0 / 14 |
Outcome results
Primary
Muscle Sympathetic Nerve Activity at Rest
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes)
Time frame: 8 weeks post treatment initiation
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Amlodipine | Muscle Sympathetic Nerve Activity at Rest | 41 bursts/minute | Standard Deviation 11.7 |
| Eplerenone | Muscle Sympathetic Nerve Activity at Rest | 43.8 bursts/minute | Standard Deviation 13 |
Secondary
Muscle Sympathetic Nerve Activity During Exercise
measurement of sympathetic nerve activity by microneurography (intraneural microelectrodes) during arm cycling exercise
Time frame: 8 weeks post treatment initiation
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Amlodipine | Muscle Sympathetic Nerve Activity During Exercise | 47 bursts/minute | Standard Deviation 16 |
| Eplerenone | Muscle Sympathetic Nerve Activity During Exercise | 51 bursts/minute | Standard Deviation 18 |